Skip to main content
17 Nov 26

news

IXICO develops a new AI tool supporting radiologists to detect vascular dysfunction in Alzheimer’s disease

Vascular dysfunction AI tool

IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces the presentation of new research in Alzheimer’s disease (AD) at the 19th Clinical Trials on Alzheimer’s Disease Conference 2026 (CTAD).

 

The research developed and evaluated an artificial intelligence (AI) tool to support radiologists in detecting cerebral microbleeds (CMBs) on magnetic resonance imaging (MRI) scans. CMBs are tiny deposits of blood in the brain that appear as small dark spots on an MRI.  They are important in AD clinical trials and treatment, because pre-existing and new microbleeds are a key vascular safety concern with anti-amyloid therapies, and patients must be monitored with repeated MRI scans. Identifying CMBs by eye is time-consuming and can vary between radiologists, which is where the newly developed tool presents a potentially significant  improvement in efficiency and accuracy.

 

The tool works in two stages: it first finds possible microbleeds across the whole brain, then examines each one to separate true CMBs from similar-looking structures such as blood vessels. On average, the IXICO developed tool detected around 90% of the microbleeds in each participant’s scan, comparing favourably to other published results, and performed consistently across studies and imaging techniques.

 

Robin Wolz, Chief Scientific Officer of IXICO, commented: “As new treatments for Alzheimer’s disease become increasingly available, the ability to monitor patient safety accurately and efficiently is more important than ever. Detecting cerebral microbleeds is a critical part of this process but remains a time-consuming task that can be subject to variability between radiologists. Our research demonstrates the potential of AI to transform this process, delivering high levels of accuracy and consistency across different MRI techniques and patient populations. This is another example of how IXICO is applying its deep expertise in neuroscience and AI to address real-world challenges in drug development and help bring new therapies to patients.”